Fresenius SE & Co. (OTCMKTS:FSNUY) Hits New 12-Month High - Still a Buy?

Key Points

• Fresenius SE & Co. shares reached a new 52-week high of $14.75, closing at $14.55, indicating strong market interest with a trading volume of over 80,000 shares.
• Analysts have placed an "overweight" rating on the stock, with one rating it a Strong Buy and two others assigning Buy ratings, resulting in an average rating of "Buy".
• The company reported earnings of $0.24 per share for the last quarter, exceeding expectations of $0.22, alongside a revenue of $6.48 billion against an anticipated $5.83 billion.

Shares of Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) hit a new 52-week high on Wednesday . The company traded as high as $14.75 and last traded at $14.55, with a volume of 80762 shares trading hands. The stock had previously closed at $14.13.

Analysts Set New Price Targets

Separately, Morgan Stanley restated an "overweight" rating on shares of Fresenius SE & Co. in a research report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy".

Fresenius SE & Co. Stock Up 3.0%

The stock has a market capitalization of $32.50 billion, a price-to-earnings ratio of 27.45 and a beta of 0.83. The company has a quick ratio of 1.00, a current ratio of 1.31 and a debt-to-equity ratio of 0.49. The business's 50-day moving average is $13.83 and its two-hundred day moving average is $12.65.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.02. The company had revenue of $6.48 billion during the quarter, compared to analysts' expectations of $5.83 billion. Fresenius SE & Co. had a return on equity of 9.33% and a net margin of 5.09%. Equities analysts anticipate that Fresenius SE & Co. will post 0.79 EPS for the current year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.